Tracon Pharmaceuticals Inc., of San Diego, reported updated data from a phase Ib trial combining TRC105 with Inlyta (axitinib, Pfizer Inc.) in patients with advanced or metastatic renal cell carcinoma at the Kidney Cancer Association meeting in Miami.